Avecho Biotechnology Limited (AU:AVE) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Avecho Biotechnology Limited reports a 30.1% drop in revenue to $312,187 and a 2.2% increase in losses to $2,175,251 for the half-year ended June 30, 2024, compared to the previous year. The decline in sales is mainly due to reduced Vital ET® sales to Ashland, while R&D expenses rose by 9% as the company advanced into Phase-III trials for its CBD soft-gel capsule for insomnia treatment. Despite higher R&D tax incentives, the company saw its net assets and working capital decrease, with no dividends declared during the period.
For further insights into AU:AVE stock, check out TipRanks’ Stock Analysis page.